Allogene announces CEO David Chang will step down

Allogene Therapeutics disclosed that its chief executive, David Chang, will be leaving the company. The firm indicated that a succession plan is in place, though it did not provide a specific timeline for the transition.

The leadership change was reported alongside other biotech developments, such as Pfizer's intention to invest billions of dollars to acquire drug candidates originating in China and the World Health Organization's recommendation to use an antiviral and two monoclonal antibodies in response to the Bundibugyo Ebola outbreak.

In addition, Replimune announced it will resubmit its experimental melanoma therapy to the U.S. Food and Drug Administration after two prior rejections. These items were highlighted in STAT+’s weekly "The Readout" newsletter.